


T. OHTA, H. ZHANG, Y. TORIHARA, I. FURUKAWA* (DOSHISHA UNIVERSITY, KYOTO, JAPAN)

Improved Synthetic Route to Dexamethasone Acetate from Tigogenin

Org. Process Res. Dev. 1997, 1, 420–424.

Synthesis of Dexamethasone



Significance: Dexamethasone is a corticosteroid that was first synthesized in 1957 and was approved in 1961 for the treatment of a wide range of inflammatory disorders. It is on the WHO List of Essential Medicines. In June 2020, dexamethasone was given preliminary approval for the treatment of COVID-19 because it improved survival rates of hospitalized patients receiving oxygen or on a ventilator. In 1997, Furukawa and co-workers reported a synthesis of dexamethasone from tigogenin.

Comment: For the introduction of the 17 α -hydroxy-16 α -methyl moiety (B \rightarrow E) the key epoxidation reaction was accomplished with peracetic acid in a buffer solution of sodium acetate and acetic acid (95% overall yield). Then the introduction of the 1,4-diene in the A-ring (H \rightarrow J, 83% yield) was greatly improved by bromination–dehydrobromination, in which dehydrobromination proceeded smoothly in a mixture of DMF and 6% of water (83% yield).

SYNFACTS Contributors: Philip Kocienski
Synfacts 2020, 16(09), 1027 Published online: 18.08.2020
DOI: 10.1055/s-0040-1705869; Reg-No.: K05820SF

© 2020, Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Category

Synthesis of Natural Products and Potential Drugs

Key words

dexamethasone
corticosteroid
tigogenin
COVID-19
conjugate addition

Synfact Classic

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.